Fatal Aplastic Anemia in a Child with Down's Syndrome
Overview
Authors
Affiliations
An infant with Down's syndrome developed severe persistent neutropenia at the age of 9 months and fluctuating anemia and thrombocytopenia at one year of age which terminated as full-blown aplastic anemia at 26 months of age. Immunological evaluation revealed increased peripheral and bone marrow lymphocytes and impaired blood OKT4: OKT8 ratio. Bone marrow granulocyte-macrophage colony forming cells (GM-CFC) were markedly increased, while peripheral blood mononuclear cells (PBMN) produced normal numbers of colonies. The patient's PBMN and serum were both somewhat inhibitory to normal bone marrow derived GM-CFC, suggesting the existence of a suppressor activity both in his serum and PBMN. This unusual course of aplastic anemia and the abnormalities in T-cells and hematopoiesis in Down's syndrome are discussed.
Immunosuppressive therapy for patients with Down syndrome and idiopathic aplastic anemia.
Suzuki K, Muramatsu H, Okuno Y, Narita A, Hama A, Takahashi Y Int J Hematol. 2016; 104(1):130-3.
PMID: 27107757 DOI: 10.1007/s12185-016-1997-z.
Furuya A, Ishida M, Hodohara K, Yoshii M, Okuno H, Horinouchi A Int J Clin Exp Pathol. 2014; 7(1):438-42.
PMID: 24427369 PMC: 3885503.
Ohwada H, Nakayama T, Nara N, Tomono Y, Yamanaka K BMC Public Health. 2006; 6:85.
PMID: 16584554 PMC: 1525175. DOI: 10.1186/1471-2458-6-85.
Captopril-induced bone marrow suppression in two cardiac patients with trisomy 21.
Gleason M, Roloff J, Cyran S, Weber H, Baylen B, Myers J Pediatr Cardiol. 1993; 14(4):227-9.
PMID: 8255797 DOI: 10.1007/BF00795376.
Raziuddin S, Elawad M Clin Exp Immunol. 1990; 79(1):67-71.
PMID: 1967994 PMC: 1534719. DOI: 10.1111/j.1365-2249.1990.tb05128.x.